Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259050 · ClinicalTrials.gov registry record · Phase 1
Safety Study of High Doses of Zinc in ALS Patients
A Phase 1 study, sponsored by Phoenix Neurological Associates.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT01259050: Completed Phase 1 study, sponsored by Phoenix Neurological Associates.
NCT01259050 is a Phase 1 study that has completed, run by Phoenix Neurological Associates. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01259050, a Phase 1 study, has completed, sponsored by Phoenix Neurological Associates.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.
Interventions
- DRUG Zinc and Copper
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
What the finished NCT01259050 record still lists
NCT01259050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Zinc and Copper is the first listed.
NCT01259050 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01259050 about?
NCT01259050 is a clinical study titled "Safety Study of High Doses of Zinc in ALS Patients". The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.
What is the current status of trial NCT01259050?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2010-10. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01259050?
The interventions under investigation include: Zinc and Copper (DRUG).
Who is sponsoring clinical trial NCT01259050?
This trial is sponsored by Phoenix Neurological Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01259050's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia